Global Rheumatoid Arthritis Drug Market Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi & Otezla) have dominated the overall anti-rheumatics market with total revenue surpassing more than US$ 25 Billion in 2016. These drugs will remain strong over the next 5 years, despite expected biosimilar competition.
Therapeutic advances have transformed the rheumatoid arthritis treatment paradigm over the last 20 years, from focusing on symptom management to now aiming for slowed disease progression and even disease remission. Disease-modifying biological medicines have ushered in a new age of treatment by targeting the cells involved in the progression of the disease.
These medicines have dramatically slowed or even reversed the negative physical effects associated with the disease and made clinical remission possible for patients with severe rheumatoid arthritis. The market of anti-rheumatics is growing at a constant speed globally. There are some driving factors which are accelerating the growth of anti-rheumatics market such as the increasing number of patients with rheumatoid arthritis, rise in research and development activities, increasing awareness among people about rheumatoid arthritis, and improved healthcare infrastructure in the region.
Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the molecular mechanisms involved. That approach changed with the introduction of biologic therapeutics at the end of the 20th century and by the recent development of small-molecule inhibitors of intracellular signal transduction pathways.
TNF-blocking biologic agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s. Further biologic agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy. During the last few years, another wave of novel discoveries led to the development of a new class of small molecule anti-inflammatory compounds targeting intracellular signal transduction molecules, such as tyrosine kinases.
The most valuable development in treating Rheumatoid Arthritis will be biomarkers to help diagnose it early, identify those with more severe disease requiring more aggressive treatment, and indicate the most appropriate therapy for each person. Biomarkers may even help to decide the best time to step down therapy when a patient is in remission. There is a huge amount of research taking place, which reflects the excellent relationships between rheumatology health care professionals and people with Rheumatoid Arthritis.
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights:
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi & Otezla) have dominated the overall anti-rheumatics market with total revenue surpassing more than US$ 25 Billion in 2016. These drugs will remain strong over the next 5 years, despite expected biosimilar competition.
Therapeutic advances have transformed the rheumatoid arthritis treatment paradigm over the last 20 years, from focusing on symptom management to now aiming for slowed disease progression and even disease remission. Disease-modifying biological medicines have ushered in a new age of treatment by targeting the cells involved in the progression of the disease.
These medicines have dramatically slowed or even reversed the negative physical effects associated with the disease and made clinical remission possible for patients with severe rheumatoid arthritis. The market of anti-rheumatics is growing at a constant speed globally. There are some driving factors which are accelerating the growth of anti-rheumatics market such as the increasing number of patients with rheumatoid arthritis, rise in research and development activities, increasing awareness among people about rheumatoid arthritis, and improved healthcare infrastructure in the region.
Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the molecular mechanisms involved. That approach changed with the introduction of biologic therapeutics at the end of the 20th century and by the recent development of small-molecule inhibitors of intracellular signal transduction pathways.
TNF-blocking biologic agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s. Further biologic agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy. During the last few years, another wave of novel discoveries led to the development of a new class of small molecule anti-inflammatory compounds targeting intracellular signal transduction molecules, such as tyrosine kinases.
The most valuable development in treating Rheumatoid Arthritis will be biomarkers to help diagnose it early, identify those with more severe disease requiring more aggressive treatment, and indicate the most appropriate therapy for each person. Biomarkers may even help to decide the best time to step down therapy when a patient is in remission. There is a huge amount of research taking place, which reflects the excellent relationships between rheumatology health care professionals and people with Rheumatoid Arthritis.
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights:
- Classification & Molecular Mechanism of Rheumatoid Arthritis Drugs
- Synthetic DMARDs as Rheumatoid Arthritis Drug
- Biological Agents as Rheumatoid Arthritis Drug
- Global Market of Rheumatoid Arthritis Drug
- Global Tendencies in Use of Antirheumatics
- Global Rheumatoid Arthritis Drug Market Future Prospect
1. ANTIRHEUMATOIDS: CALL OF RHEUMATOID ARTHRITIS
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis
2. MOLECULAR MECHANISM OF ANTIRHEUMATOIDS
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 & IL-6 Blockers
3. CLASSIFICATION OF RHEUMATOID ARTHRITIS DRUGS
3.1 Traditional Classification of Rheumatoid Arthritis Drugs
3.2 New Proposed Classification of DMARDs
4. SYNTHETIC DMARDS AS RHEUMATOID ARTHRITIS DRUG
4.1 Methotrexate (MTX)
4.2 Sulfasalazine (SSZ)
4.3 Leflunomide
4.4 Hydroxychloroquine (HCQ)
5. BIOLOGICAL AGENTS AS RHEUMATOID ARTHRITIS DRUG
5.1 Cytokine Inhibitors
5.1.1 Etanercept (Enbrel)
5.1.2 Infliximab (Remicade)
5.1.3 Adalimumab (Humira)
5.1.4 Golimumab (Simponi)
5.1.5 Certolizumab pegol (Cimzia)
5.2 Interleukin 1 & Interleukin 6 Inhibitors
5.2.1 Anakinra (Kineret)
5.2.2 Tocilizumab (RoActerma)
5.3 T-Cell & B-Cell Inhibitors
5.3.1 Abatacept (Orencia)
5.3.2 Rituximab (Mabthera)
6. GLOBAL PREVALENCE OF RHEUMATOID ARTHRITIS
6.1 US
6.2 Europe
6.3 Canada
6.4 Asia
7. GLOBAL TENDENCIES IN USE OF ANTIRHEUMATICS
7.1 Trail from Conventional to Biological DMARDs
7.2 Global Trends of Antirheumatic Prescription
8. GLOBAL MARKET OF RHEUMATOID ARTHRITIS DRUG
8.1 Market Overview of DMARDs
8.2 Market of Biosimilar DMARDs
8.3 Top Leading DMARDs by Revenues (2015 & 2022)
8.3.1 Humira (Adalimumab)
8.3.2 Enbrel (Etanercept)
8.3.3 Remicade
8.3.4 Simponi
8.3.5 Otezla (Celgene)
9. GLOBAL RHEUMATOID ARTHRITIS DRUGMARKET DYNAMICS
9.1 Accelerative Parameters
9.2 Challenges
10. GLOBAL RHEUMATOID ARTHRITIS DRUG MARKET FUTURE PROSPECT
11. COMPETITIVE LANDSCAPE
11.1 Abbvie
11.2 Biogen Idec
11.3 Bristol-Myers Squibb
11.4 Celgene
11.5 Celltrion
11.6 J&J
11.7 MedImmune
11.8 Merck
11.9 Novartis
11.10 Takeda
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis
2. MOLECULAR MECHANISM OF ANTIRHEUMATOIDS
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 & IL-6 Blockers
3. CLASSIFICATION OF RHEUMATOID ARTHRITIS DRUGS
3.1 Traditional Classification of Rheumatoid Arthritis Drugs
3.2 New Proposed Classification of DMARDs
4. SYNTHETIC DMARDS AS RHEUMATOID ARTHRITIS DRUG
4.1 Methotrexate (MTX)
4.2 Sulfasalazine (SSZ)
4.3 Leflunomide
4.4 Hydroxychloroquine (HCQ)
5. BIOLOGICAL AGENTS AS RHEUMATOID ARTHRITIS DRUG
5.1 Cytokine Inhibitors
5.1.1 Etanercept (Enbrel)
5.1.2 Infliximab (Remicade)
5.1.3 Adalimumab (Humira)
5.1.4 Golimumab (Simponi)
5.1.5 Certolizumab pegol (Cimzia)
5.2 Interleukin 1 & Interleukin 6 Inhibitors
5.2.1 Anakinra (Kineret)
5.2.2 Tocilizumab (RoActerma)
5.3 T-Cell & B-Cell Inhibitors
5.3.1 Abatacept (Orencia)
5.3.2 Rituximab (Mabthera)
6. GLOBAL PREVALENCE OF RHEUMATOID ARTHRITIS
6.1 US
6.2 Europe
6.3 Canada
6.4 Asia
7. GLOBAL TENDENCIES IN USE OF ANTIRHEUMATICS
7.1 Trail from Conventional to Biological DMARDs
7.2 Global Trends of Antirheumatic Prescription
8. GLOBAL MARKET OF RHEUMATOID ARTHRITIS DRUG
8.1 Market Overview of DMARDs
8.2 Market of Biosimilar DMARDs
8.3 Top Leading DMARDs by Revenues (2015 & 2022)
8.3.1 Humira (Adalimumab)
8.3.2 Enbrel (Etanercept)
8.3.3 Remicade
8.3.4 Simponi
8.3.5 Otezla (Celgene)
9. GLOBAL RHEUMATOID ARTHRITIS DRUGMARKET DYNAMICS
9.1 Accelerative Parameters
9.2 Challenges
10. GLOBAL RHEUMATOID ARTHRITIS DRUG MARKET FUTURE PROSPECT
11. COMPETITIVE LANDSCAPE
11.1 Abbvie
11.2 Biogen Idec
11.3 Bristol-Myers Squibb
11.4 Celgene
11.5 Celltrion
11.6 J&J
11.7 MedImmune
11.8 Merck
11.9 Novartis
11.10 Takeda
LIST OF FIGURES
Figure 1-1: Representation of the Disease Progression in Rheumatoid Arthritis
Figure 2-1: Mechanism of Action of Anti-TNF in Rheumatoid Arthritis Treatment
Figure 3-1: Classified Antirheumatic Drugs Pattern in Course of Treatment
Figure 3-2: Demonstration of New Nomenclature for Antirheumatic Drugs
Figure 4-1: Structure of Several Synthetic Antirheumatic DMARDs
Figure 5-1: ACR Response Rate of Infliximab vs. Biosimilar CT-P13
Figure 5-2: Immunoglobulin Structures of the TNF Agonists including all Five Classes
Figure 6-1: Worldwide Prevalence of Rheumatoid Arthritis
Figure 6-2: Percentage of Rheumatoid Arthritis by Gender in US
Figure 6-3: Prevalence of Rheumatoid Arthritis over Ethnicity
Figure 6-4: Incidence of Rheumatoid Arthritis with Increasing Age
Figure 6-5: Illustration of Upcoming Risk of RA in US
Figure 6-6: Illustration of Percentage of Prevalence of Rheumatic Arthritis
Figure 6-7: Projected Number of Individuals with Rheumatism in Canada
Figure 7-1: Traditional Mode of Rheumatoid Arthritis Treatment
Figure 7-2: Illustration of Changes in Use of DMARDs after MTX
Figure 7-3: US: Percentage of Type of DMARDs Used for RA in 2013
Figure 8-1: Global - Rheumatoid Arthritis Drug Sales (US$ Billion), 2015-2022
Figure 8-2: Patent Expiration of Major Antirheumatic Drugs under Biologics in EU & US
Figure 8-3: Global - Top Rheumatoid Arthritis Drugs by Revenue from 2015 & 2022
Figure 8-4: Global – Share of Top Rheumatoid Arthritis Drugs in Market (%),2022
Figure 8-5: Global - Humira Sales (US$ Billion), 2011-2015 & 2022
Figure 8-6: Global - Enbrel Sales (US$ Billion), 2015- 2016 & 2022
Figure 8-7: Global – Remicade Sales (US$ Billion), 2015 & 2022
Figure 8-8: Global Percentage of Simponi Sale Revenues by Region (2015-2022) (Billions)
Figure 8-9: Global – Simponi Sales (US$ Billion), 2015 & 2022
Figure 8-10: Global - Otezela Sales (US$ Billion) 2015 & 2022
Figure 9-1: Major Driving Forces of Antirheumatics Drug Market
Figure 9-2: Increasing Market Size of Biosimilars Worldwide
Figure 9-3: Major Challenges faced by Antirheumatics Market
Figure 9-4: Average Annual Treatment Cost of Humira, Enbrel & Remicade (US$), 2014
Figure 10-1: Global - Rheumatoid Arthritis Drug Market by Drug Class (TNF Inhibitors, JAK Inhibitors & Others) 2022
Figure 1-1: Representation of the Disease Progression in Rheumatoid Arthritis
Figure 2-1: Mechanism of Action of Anti-TNF in Rheumatoid Arthritis Treatment
Figure 3-1: Classified Antirheumatic Drugs Pattern in Course of Treatment
Figure 3-2: Demonstration of New Nomenclature for Antirheumatic Drugs
Figure 4-1: Structure of Several Synthetic Antirheumatic DMARDs
Figure 5-1: ACR Response Rate of Infliximab vs. Biosimilar CT-P13
Figure 5-2: Immunoglobulin Structures of the TNF Agonists including all Five Classes
Figure 6-1: Worldwide Prevalence of Rheumatoid Arthritis
Figure 6-2: Percentage of Rheumatoid Arthritis by Gender in US
Figure 6-3: Prevalence of Rheumatoid Arthritis over Ethnicity
Figure 6-4: Incidence of Rheumatoid Arthritis with Increasing Age
Figure 6-5: Illustration of Upcoming Risk of RA in US
Figure 6-6: Illustration of Percentage of Prevalence of Rheumatic Arthritis
Figure 6-7: Projected Number of Individuals with Rheumatism in Canada
Figure 7-1: Traditional Mode of Rheumatoid Arthritis Treatment
Figure 7-2: Illustration of Changes in Use of DMARDs after MTX
Figure 7-3: US: Percentage of Type of DMARDs Used for RA in 2013
Figure 8-1: Global - Rheumatoid Arthritis Drug Sales (US$ Billion), 2015-2022
Figure 8-2: Patent Expiration of Major Antirheumatic Drugs under Biologics in EU & US
Figure 8-3: Global - Top Rheumatoid Arthritis Drugs by Revenue from 2015 & 2022
Figure 8-4: Global – Share of Top Rheumatoid Arthritis Drugs in Market (%),2022
Figure 8-5: Global - Humira Sales (US$ Billion), 2011-2015 & 2022
Figure 8-6: Global - Enbrel Sales (US$ Billion), 2015- 2016 & 2022
Figure 8-7: Global – Remicade Sales (US$ Billion), 2015 & 2022
Figure 8-8: Global Percentage of Simponi Sale Revenues by Region (2015-2022) (Billions)
Figure 8-9: Global – Simponi Sales (US$ Billion), 2015 & 2022
Figure 8-10: Global - Otezela Sales (US$ Billion) 2015 & 2022
Figure 9-1: Major Driving Forces of Antirheumatics Drug Market
Figure 9-2: Increasing Market Size of Biosimilars Worldwide
Figure 9-3: Major Challenges faced by Antirheumatics Market
Figure 9-4: Average Annual Treatment Cost of Humira, Enbrel & Remicade (US$), 2014
Figure 10-1: Global - Rheumatoid Arthritis Drug Market by Drug Class (TNF Inhibitors, JAK Inhibitors & Others) 2022
